Pacira Pharma (PCRX) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update
March 1, 2017 7:30 AM EST-- Phase 4 EXPAREL® study in total knee arthroplasty meets co-primary endpoints for pain control and opioid reduction against an active comparator ---- EXPAREL net product sales up 11% year-over-year ---- EXPAREL net product sales expected to be in the range of $290 to $310 million in 2017 ---- Conference call today at 8:30 a.m. ET --
PARSIPPANY, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals,... More
